This content is machine translated Chronic inflammatory bowel disease Ustekinumab approved in Switzerland for ulcerative colitis Swissmedic approves the use of the monoclonal antibody for the treatment of moderate to severe active ulcerative colitis where treatment goals are not achieved with conventional therapy.
